SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: Case series

J Dtsch Dermatol Ges. 2024 Aug;22(8):1161-1165. doi: 10.1111/ddg.15453. Epub 2024 May 22.
No abstract available

Keywords: Adverse drug reaction; bullous disorders; enfortumab; immunotherapy; pembrolizumab.

Publication types

  • Letter
  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Drug Eruptions / diagnosis
  • Drug Eruptions / etiology
  • Female
  • Humans
  • Male
  • Middle Aged

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab